Abstract:The central role of platelets in thrombosis is well characterized. Recently, evidence has emerged that platelets also play crucial roles in inflammation and cancer. Therefore, reliable and sensitive imaging of activated platelets holds promise to improve diagnosis in numerous diseases and addresses a significant clinical need. 1 Here, we describe an innovative method for imaging activated platelets using advanced fluorine‐19 ( 19 F) magnetic resonance imaging (MRI). MRI provides high‐resolution imaging, even in deep tissues, without harmful ionizing radiation. Visualization of thrombi, inflammation, early cancer, and metastases is difficult since these structures are often not well differentiated against surrounding tissues. MRI contrast based on gadolinium or iron oxide has been employed to improve tissue differentiation. However, these contrast agents are imaged using conventional hydrogen ( 1 H)‐based MRI and are sometimes difficult to differentiate from anatomical structure. An alternative, 19 F‐based MRI holds promise for greater specificity. 19 F is essentially absent from biological tissue, allowing for background‐free localization. The merge of 1 H and 19 F data sets allows for exact anatomical localization and molecular characterization. Furthermore, the linear relationship between fluorine concentration and signal intensity permits direct quantification of contrast agent accumulation. 19 F MRI contrast agents are typically generated using perfluorocarbons, which are chemically and biologically inert, rendering them safe for in vivo use. 2 Perfluorocarbons are emulsified with phospholipids to form stable, biocompatible, and intravenously administrable nanoemulsions (PFCs). Non‐conjugated PFCs are phagocytosed by monocytes/macrophages, a method utilized for imaging of inflammation in mouse models of myocardial and cerebral ischemia, myocarditis, and pneumonia. 1 Direct targeting of PFCs, independent of phagocytosis, using small antiplasmin peptide–conjugated PFCs were successfully employed to detect the early phase of venous thrombosis via 19 F MRI. 3 To achieve selective targeting of activated platelets, we chose to target the activated conformation of integrin glycoprotein IIb/IIIa (GPIIb/IIIa; α IIb β 3 , CD41/CD61). GPIIb/IIIa is highly specific for platelets and is the most abundantly expressed receptor on the platelet surface (≈60 000 receptors per platelet). Upon platelet activation, GPIIb/IIIa undergoes a conformational change with the selective exposure of specific epitopes. 4 We generated a unique human single‐chain antibody (scFv), that binds specifically to the activated conformation of GPIIb/IIIa (scFv Targ ), and exhibits the same binding profile on human and mouse platelets, providing a distinct advantage for cross‐species testing. 4 , 5 The scFv Targ does not bind to nonactivated circulating platelets or to other proteins or cells in the blood. 4 This scFv Targ has been successfully used for molecular imaging of diseases across a range of imaging technologies, including ultrasound, positron emission tomography, fluorescence emission computed tomography, and conventional MRI. 1 , 4 , 5 We have now established an antibody‐targeted, 19 F‐based MRI approach that enables selective imaging of activated platelets, with a large scope of potential applications, such as in the diagnosis of atherothrombotic, inflammatory, and malignant diseases. For imaging of activated platelets by 19 F MRI, we generated dual‐modality PFCs, which were functionalized with a biotin‐lipid for conjugation with the scFv and a fluorescence dye. PFCs containing 0.01 mol% biotin‐DHPE were coated with neutravidin and washed by centrifugation. Biotinylated scFv Targ was then coupled to the neutravidin moiety of the perfluorocarbons ( Targ PFCs). As a control, we conjugated a non‐targeted, nonbinding scFv Non‐targ to the PFCs ( Non‐targ PFCs). Targeting properties of these PFCs were confirmed using a flow‐chamber adhesion assay using human blood 4 , <a class="t -Abstract Truncated-

Fluorine-19 Magnetic Resonance Imaging of Activated Platelets.

18F Site-Specific Labelling of a Single-Chain Antibody against Activated Platelets for the Detection of Acute Thrombosis in Positron Emission Tomography

Molecular Imaging of Activated Platelets Via Antibody-Targeted Ultra-Small Iron Oxide Nanoparticles Displaying Unique Dual MRI Contrast.

Experimental Study of Interaction Between Activated VWF and Targeted Lipid Microbubbles Conjugated with Recombinant GPIba

A Unique Recombinant Fluoroprobe Targeting Activated Platelets Allows In Vivo Detection of Arterial Thrombosis and Pulmonary Embolism Using a Novel Three-Dimensional Fluorescence Emission Computed Tomography (FLECT) Technology

Conformation-specific blockade of the integrin GPIIb/IIIa: a novel antiplatelet strategy that selectively targets activated platelets

An RGD Modified Water-Soluble Fluorophore Probe for in Vivo NIR-II Imaging of Thrombosis.

Dual‐modality Imaging for Identifying Thrombosis Via Platelet GPIIb/IIIa Receptor Targeted Cyclic RGDfK Microbubbles

Mr Molecular Imaging of Thrombus: Development and Application of A Gd-Based Novel Contrast Agent Targeting to P-Selectin

Human Platelets Repurposed As Vehicles for in Vivo Imaging of Myeloma Xenotransplants

Customizable, multi-functional fluorocarbon nanoparticles for quantitative in vivo imaging using 19F MRI and optical imaging

Perfluorocarbons-Based 19F Magnetic Resonance Imaging in Biomedicine

Targeted Molecular Iron Oxide Contrast Agents for Imaging Atherosclerotic Plaque

Self‐assembled Fluorinated Nanoparticles as Sensitive and Biocompatible Theranostic Platforms for 19f Mri

Qualitative and quantitative analysis of 18F-GP1 positron emission tomography in thrombotic cardiovascular disease

18F-labeled tracers targeting fibroblast activation protein

Imaging of thromboembolism with ~(99)Tc~m-SZ21F(ab)_2,a humanized anti-platelet glycoprotein IIIa monoclonai antibody F(ab)_2 fragment

Bio-orthogonal Metabolic Fluorine Labeling Enables Deep-Tissue Visualization of Tumor Cells in Vivo by 19F Magnetic Resonance Imaging.

Imaging Thromboembolism with 99mtc Labelled Chimeric Monoclonal Anti-Platelet Glycoprotein Iiia Antibody Fragment Chsz21f(ab)2: Evaluation in Beagle Canines

Phosphatidylserine-targeted molecular imaging of tumor vasculature by magnetic resonance imaging.

High F-Content Perfluoropolyether-Based Nanoparticles for Targeted Detection of Breast Cancer by 19F Magnetic Resonance and Optical Imaging